What matters most: the tax status of an investment, or its quality? You might think the answer is obvious. But that hasn’t stopped large numbers of people putting money in risky, but potentially tax-advantageous products, rather than simply in good investments. Some are regretting it this week.
First up in the regret stakes will be anyone who piled money into the Oxford Technology venture capital trust (VCT) and Oxford Technology 3 VCT in the last couple of years. The funds hold shares in Scancell, an Aim-listed vaccine firm.
A sharp rise in the share price took the value [...]
Want to read this article now?
Already a MoneyWeek subscriber? Please log in below.
Not a subscriber? Sign-up now for a 4 week FREE trial to get instant access.